| For: | Holst F. Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. World J Clin Oncol 2016; 7(2): 160-173 [PMID: 27081639 DOI: 10.5306/wjco.v7.i2.160] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v7/i2/160.htm |
| Number | Citing Articles |
| 1 |
Tomás Reinert, Guilherme Portela Coelho, Jovana Mandelli, Edinéia Zimermann, Facundo Zaffaroni, José Bines, Carlos Henrique Barrios, Marcia Silveira Graudenz. Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. Journal of Oncology 2019; 2019 doi: 10.1155/2019/1947215
|
| 2 |
Yi-Fang Yang, Yu-Chan Chang. The role of the ESR1 gene in breast cancer: A comprehensive review of detailed analysis of biology, mutational landscapes, pathways, and therapeutic implications. Tungs' Medical Journal 2026; doi: 10.4103/ETMJ.ETMJ-D-25-00055
|
| 3 |
Luiz Gustavo de Almeida Chuffa, Luiz Antonio Lupi-Júnior, Aline Balandis Costa, João Paulo de Arruda Amorim, Fábio Rodrigues Ferreira Seiva. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids 2017; 118 doi: 10.1016/j.steroids.2016.12.011
|
| 4 |
Anna Kawiak, Anna Kostecka. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. Cancers 2022; 14(2) doi: 10.3390/cancers14020279
|
| 5 |
Ahmed Basudan, Nolan Priedigkeit, Ryan J. Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca J. Watters, Michelle M. Boisen, Rohit Bhargava, Kurt R. Weiss, Maria M. Karsten, Carsten Denkert, Jens-Uwe Blohmer, Jose P. Leone, Ronald L. Hamilton, Adam M. Brufsky, Esther Elishaev, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research 2019; 17(2) doi: 10.1158/1541-7786.MCR-18-0946
|
| 6 |
Monika Bar, Wiesława Widłak, Natalia Vydra. Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER+ Breast Cancer. International Journal of Cancer 2026; doi: 10.1002/ijc.70522
|
| 7 |
Asaad Azarnezhad, Mina Tabrizi, Morteza Atri, Parvin Mehdipour.
ESR1
Gene Amplification in an Iranian Population with Early Onset Invasive Ductal Breast Carcinoma
. Breast Cancer Management 2018; 7(2) doi: 10.2217/bmt-2017-0018
|
| 8 |
Anwar Parvez, Najmun Nahar Sweety, A S M Abdur Rouf, Md Mahfuzur Rahman, Abdullah Al Noman, Pranab Dev Sharma, Md. Ekramul Haque, Md Al Mamun. Clerodendrum infortunatum (CI) Against Breast Cancer (BC) and Evaluating Its Cytotoxic Activity: A Combined In Silico and In Vivo Approach. ChemistrySelect 2026; 11(2) doi: 10.1002/slct.202504703
|
| 9 |
Lan Cao, Ahmed Basudan, Matthew J. Sikora, Amir Bahreini, Nilgun Tasdemir, Kevin M. Levine, Rachel C. Jankowitz, Priscilla F. McAuliffe, David Dabbs, Sue Haupt, Ygal Haupt, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich, Jennifer M. Atkinson. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters 2019; 461 doi: 10.1016/j.canlet.2019.06.011
|
| 10 |
Irina Gaynanova, Tianying Wang. Sparse quadratic classification rules via linear dimension reduction. Journal of Multivariate Analysis 2019; 169 doi: 10.1016/j.jmva.2018.09.011
|
| 11 |
Sarah R. Hosford, Kevin Shee, Jason D. Wells, Nicole A. Traphagen, Jennifer L. Fields, Riley A. Hampsch, Arminja N. Kettenbach, Eugene Demidenko, Todd W. Miller. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer. Molecular Oncology 2019; 13(8) doi: 10.1002/1878-0261.12528
|
| 12 |
Piera Rizzolo, Anna Sara Navazio, Valentina Silvestri, Virginia Valentini, Veronica Zelli, Ines Zanna, Giovanna Masala, Simonetta Bianchi, Marco Scarnò, Stefania Tommasi, Domenico Palli, Laura Ottini. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. Oncotarget 2016; 7(45) doi: 10.18632/oncotarget.12272
|
| 13 |
Christian F. Singer, Frederik Holst, Stefan Steurer, Eike C. Burandt, Sigurd F. Lax, Raimund Jakesz, Margaretha Rudas, Herbert Stöger, Richard Greil, Guido Sauter, Martin Filipits, Ronald Simon, Michael Gnant. Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer. Clinical Cancer Research 2022; 28(18) doi: 10.1158/1078-0432.CCR-21-4328
|
| 14 |
Carlos Martínez-Pérez, Arran K Turnbull, J Michael Dixon. The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy 2019; 19(2) doi: 10.1080/14737140.2019.1552138
|
| 15 |
Chi-Cheng Huang, Yi-Fang Tsai, Chun-Yu Liu, Ta-Chung Chao, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Jen-Hwey Chiu, Chih-Yi Hsu, Ling-Ming Tseng. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-07931-4
|
| 16 |
Hitisha K. Patel, Teeru Bihani. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics 2018; 186 doi: 10.1016/j.pharmthera.2017.12.012
|
| 17 |
Stéphanie L. Gaillard, Kaitlyn J. Andreano, Laurie M. Gay, Meghan Steiner, Matthew S. Jorgensen, Brittany Anne Davidson, Laura J. Havrilesky, Angeles Alvarez Secord, Fidel A. Valea, Gerardo Colon-Otero, Deborah A. Zajchowski, Ching-Yi Chang, Donald P. McDonnell, Andrew Berchuck, Julia A. Elvin. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecologic Oncology 2019; 154(1) doi: 10.1016/j.ygyno.2019.04.010
|
| 18 |
Anna Nagel, Jolanta Szade, Mariola Iliszko, Julia Elzanowska, Marzena Welnicka-Jaskiewicz, Jaroslaw Skokowski, Grzegorz Stasilojc, Jacek Bigda, Rafal Sadej, Anna Zaczek, Aleksandra Markiewicz. Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients. International Journal of Molecular Sciences 2019; 20(8) doi: 10.3390/ijms20081881
|
| 19 |
Frederik Holst, Christian F. Singer. ESR1 -Amplification-Associated Estrogen Receptor α Activity in Breast Cancer. Trends in Endocrinology & Metabolism 2016; 27(11) doi: 10.1016/j.tem.2016.08.002
|
| 20 |
Wenbin Ma, Sara Herrera-Rodriguez, Hector Martinez-Valdez. Personalized Pathway-Activated Systems Imaging in Oncology. 2017; doi: 10.1007/978-981-10-3349-0_7
|
| 21 |
Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz. ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00342
|
| 22 |
Azadeh Nasrazadani, Roby A. Thomas, Steffi Oesterreich, Adrian V. Lee. Precision Medicine in Hormone Receptor-Positive Breast Cancer. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00144
|
| 23 |
Yasmin M. Vasquez, W. Lee Kraus. Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development 2019; doi: 10.1007/978-3-319-99350-8_5
|